Chiara Naro

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Claudio Sette · 3 shared papers, 2021–2025 · strength 0.71
   • Paper Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer. DOI 10.1016/j.molmed.2024.11.007↗
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
   • Paper The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal ad… DOI 10.1002/1878-0261.12847↗
2. Veronica Ruta · 2 shared papers, 2024–2025 · strength 0.59
   • Paper Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer. DOI 10.1016/j.molmed.2024.11.007↗
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
3. Valentina Panzeri · 2 shared papers, 2021–2024 · strength 0.28
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
   • Paper The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal ad… DOI 10.1002/1878-0261.12847↗
4. Gabriele Capurso · 2 shared papers, 2021–2024 · strength 0.28
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
   • Paper The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal ad… DOI 10.1002/1878-0261.12847↗
5. Chantal Allgöwer · 1 shared paper, 2024 · strength 0.16
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
6. Giuseppe Quero · 1 shared paper, 2024 · strength 0.16
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
7. Claudio Doglioni · 1 shared paper, 2024 · strength 0.16
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
8. Sergio Alfieri · 1 shared paper, 2024 · strength 0.16
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
9. Lívia Archibugi · 1 shared paper, 2024 · strength 0.16
   • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
10. Adriana Leccese · 1 shared paper, 2024 · strength 0.16
    • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
11. Alexander Kleger · 1 shared paper, 2024 · strength 0.16
    • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
12. Giampaolo Tortora · 1 shared paper, 2024 · strength 0.16
    • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
13. Massimo Falconi · 1 shared paper, 2024 · strength 0.16
    • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
14. Paolo Giorgio Arcidiacono · 1 shared paper, 2024 · strength 0.16
    • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
15. Carmine Carbone · 1 shared paper, 2024 · strength 0.16
    • Paper An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic ca… DOI 10.1016/j.xcrm.2024.101411↗
16. Luisa de Latouliere · 1 shared paper, 2021 · strength 0.12
    • Paper The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal ad… DOI 10.1002/1878-0261.12847↗
17. Giulia Piaggio · 1 shared paper, 2021 · strength 0.12
    • Paper The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal ad… DOI 10.1002/1878-0261.12847↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.